{"page":{"totalFilteredElements":330},"studies":[{"active":true,"description":"RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma","eudractNumber":"2025-525088-34","id":11727,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-10-08T12:02:49+02:00","shortTitle":"RASOLUTE 303","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A PHASE 2 AND PHASE 3 PERI-OPERATIVE TRIAL OF FIANLIMAB AND \nCEMIPLIMAB COMPARED WITH ANTI-PD1 ALONE IN PATIENTS WITH \nRESECTABLE STAGE III AND IV MELANOMA","eudractNumber":"2022-502825-17-00","id":9882,"indications":[{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"LAG-3","id":"mt_39"}],"nctNumber":"NCT06190951","phase":{"id":"ph_8","name":"Phase II/III"},"recruitmentStart":"2025-10-09T09:45:47+02:00","shortTitle":"REGENERON / R3767-ONC-2208","therapeutical":true,"therapyLines":[{"id":"tl_6","name":"Adjuvant"},{"id":"tl_7","name":"Neoadjuvant"}]},{"active":true,"description":"<b>Ropeginterferon alfa-2b bei Patienten mit Polycythemia\nvera</b>","eudractNumber":null,"id":11329,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-09-15T09:30:26+02:00","shortTitle":"ROPE","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Registerplattform H&#228;matologische Neoplasien (RUBIN) - Erweiterung des Tumorregisters Lymphatische Neoplasien","eudractNumber":null,"id":9911,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06043011","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2023-10-23T15:03:12+02:00","shortTitle":"RUBIN","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"","eudractNumber":null,"id":11211,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":null,"shortTitle":"ReBaVeCo","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prospective study with continuous and fixed-Duration Ibrutinib based First Line Treatment in patients with Chronic Lymphocytic Leukemnia in real world setting","eudractNumber":null,"id":9253,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-03-03T15:05:01+01:00","shortTitle":"Reality 2","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Simultan integrierter Boost in der HNO Quality Control Registry","eudractNumber":null,"id":2554,"indications":[{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno3","name":"Kopf-Hals-Malignome"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06831903","phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2019-10-01T13:37:34+02:00","shortTitle":"Register SIB HNO","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Register und Biobank\nseltene maligne Tumoren der Schilddr&#252;se und Nebenschilddr&#252;sen","eudractNumber":null,"id":1811,"indications":[{"id":"sch","name":"Schilddrüsenkarzinom"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2013-10-04T09:56:39+02:00","shortTitle":"Register und Biobank für seltene maligne Tumoren der Schilddrüse und Nebenschilddrüsen","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"<div><div><div>Male breast cancer - A prospective registry study of the University Women's Hospital Magdeburg in cooperation with the GBG (German Breast Group) on the diagnosis and treatment of male breast cancer</div><div><br /></div><div>DRKS00009536</div></div><div><br /></div></div>","eudractNumber":null,"id":6191,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2009-09-08T10:20:42+02:00","shortTitle":"Registerstudie Mammakarzinom des Mannes","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Mammakarzinom des Mannes - Eine prospektive Registerstudie der Universit&#228;tsfrauenklinik Magdeburg in Zusammenarbeit mit der GBG (German Breast Group) zur Diagnostik und Therapie des Mammakarzinoms des Mannes<div><br /></div><div>DRKS00009536</div>","eudractNumber":null,"id":1491,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2009-04-01T14:07:15+02:00","shortTitle":"Registerstudie Mammakarzinom des Mannes","therapeutical":false,"therapyLines":[]}]}